Table 1 CXCL9 expression in human tumor biopsies treated ex vivo with galectin antagonists.

From: Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration

Tumor code Tumor type Untreated (*) LacNAc IFNγ IFNγ + galectins antagonists
      LacNAc GM-CT-01 αGal3 mIgG1 αGal3 ratIgG
13-121 Neuroendocrina 1 (3) 51 317 281 N/A N/A N/A
14-031 Adenocarcinoma 1 (12) 1 5 2 2 N/A N/A
13-212 Adenocarcinoma 1 (33) 15 7 82 N/A N/A N/A
14-286 Renal carcinoma 1 (67) N/A 36 91   242 N/A
14-581 Pancreatic carcinoma 1 (77) 29 112 392 251 31 8
13-248 Adenocarcinoma 1 (78) 2 1 3 N/A N/A N/A
13-480 Adenocarcinoma 1 (89) 0 2 73 12 N/A N/A
15-426 Uterine carcinoma 1 (139) 2 2 5 10 1 1
12-477 Adenocarcinoma 1 (168) 1 1 2 N/A N/A N/A
13-298 Adenoma 1 (193) 2 2 5 N/A N/A N/A
13-568 Hepatoadenoma 1 (268) 1 5 11 9 N/A N/A
LB-3422 Melanoma 1 (379) 0 1 16 2 N/A N/A
14-063 Adenocarcinoma 1 (399) 5 7 14 14 N/A N/A
14-583 Adenocarcinoma 1 (406) N/A 2 7 2 4 8
15-427 Adenocarcinoma 1 (489) 1 3 3 2 3 2
15-228 Sarcoma 1 (972) 2 98 193 195 116 138
14-187 Rectal adenocarcinoma 1 (1065) 1 1 5 3 N/A N/A
13-420 Lymphoma B diffuse 1 (1278) 2 2 2 N/A N/A N/A
14-526 Renal carcinoma 1 (1287) 2 3 3 3 1 2
13-454 Adenocarcinoma 1 (1287) 1 2 1 N/A N/A N/A
12-529 Hepatoblastoma 1 (1628) 4 3 8 N/A N/A N/A
14-239 Renal carcinoma 1 (3321) 1 2 2 1 1 N/A
12-549 Leiomyoma 1 (8056) 14 5 33 40 N/A N/A
  1. Fold induction CXCL9 values using HPRT-1 as a reference gene and with respect to the untreated condition (2−ΔΔCt). For the untreated condition, CXCL9 mRNA levels normalized to HPRT-1 (103 × 2−ΔCt) are indicated in brackets. Human biopsies were treated for 6 h with IFNγ (50 ng ml−1), LacNAc (10 mM), GM-CT-01 (100 μg ml−1), and/or anti-galectin-3 antibodies (10 μg ml−1)
  2. N/A no available data